Trecator

(Ethionamide)

PreclinicalSmall molecule

WWyeth-Lederle Vaccines

Trecator is one of 62 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pulmonary TuberculosisActive, not recruiting

TuberculosisActive, not recruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

TuberculosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

297 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Multivitamin

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

1 2

Rifapentine Plus Isoniazid

HHuashan Hospital

Phase 3

1 3

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

22 4

Rifapentine and Moxifloxacin

CCenters for Disease Control and Prevention

Phase 3

3 5

ESAT6-CFP10

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Phase 3

3 6

Gamtbvac

GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Phase 3

2 7

Tivicay

GSK

Preclinical

4 8

Norvir

AbbVie

Preclinical

1 9

Revia

Teva

Preclinical

1 10

Vemlidy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

NAC

NCT05807399

Clinical

Trials by Indication[1]

NAC1 trial

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

Pulmonary Tuberculosis1 trial

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled

Tuberculosis1 trial

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Completed·UUniversity of Cape Town·Phase 2/3·NCT02454205·154 enrolled

Phase 21 trial

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

Completed·TTASK Applied Science·Phase 2·NCT05473195·105 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TRECATOR

NDA NDA013026

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ethionamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ethionamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ethionamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013026). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWyeth-Lederle Vaccines

Trecator

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

NAC1 trial

Pulmonary Tuberculosis1 trial

Tuberculosis1 trial

Phase 21 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News